# Psychiatry For Patients with Hyperactivity and The Role Of Medications And Tests

<sup>1</sup>Saad Nasser AlShetwi, <sup>2</sup>Abdullah Saleh Alhamad, <sup>3</sup>Abdulrahman Saad AlZeer, <sup>4</sup>Muteb Rasheed AlMutib

<sup>1</sup>Pharmacy tech, Head quarter PHC

<sup>2</sup>Lab Tech, Head Quarter PHC

<sup>3</sup>Psychologist, health affairs national guard

<sup>4</sup>Nursing health assistant, Head Quarter PHC

Corresponding Author: Saad Nasser AlShetwi

#### Abstract-

Psychiatry plays a crucial role in treating patients with hyper, such as those Attention Deficit Hyperactivity Disorder (ADHD). Medications and tests are common tools used in the management of hyperactivity in patients. This essay explores the role of psychiatric medications and tests in the treatment of hyperactivity in patients. The method involves a review of relevant literature on the topic, with a focus on studies that examine the efficacy and safety of medications and tests in patients with hyperactivity. The results suggest that medications and tests play a significant role in the treatment of hyperactivity, with various options available for patients. The discussion delves into the benefits and limitations of psychiatric medications and tests, emphasizing the importance of individualized treatment plans. In conclusion, psychiatry offers valuable interventions for patients with hyperactivity, and further research is needed to enhance treatment options.

Keywords: Psychiatry, hyperactivity, medications, tests, ADHD.



Published in IJIRMPS (E-ISSN: 2349-7300), Volume 4, Issue 2, March-April 2016

License: Creative Commons Attribution-ShareAlike 4.0 International License





## Introduction

Patients with hyperactivity, such as those with ADHD, often require specialized psychiatric care to manage their symptoms effectively. Psychiatry offers various treatment modalities, including medications and tests, to address the underlying causes of hyperactivity and improve patients' quality of. This essay aims to explore the role of psychiatric medications and tests in the treatment of hyperactivity in patients.

When it comes to patients with hyperactivity, psychiatry plays a significant role in assessment, diagnosis, and treatment. Attention-deficit/hyperactivity disorder (ADHD) is a common condition associated with hyperactivity, and psychiatric interventions, along with appropriate medications and tests, are often utilized. Let's delve into these aspects:

## Assessment and Diagnosis:

- a. Clinical Evaluation: A comprehensive clinical evaluation, conducted by a psychiatrist or mental health professional, is crucial. It involves obtaining a detailed history, assessing symptoms, observing behavior, and evaluating the impact of hyperactivity on daily functioning.
- b. Diagnostic Criteria: The psychiatrist will refer to standardized diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), to determine if the patient meets the criteria for ADHD or any other related conditions.
- c. Rating Scales: Rating scales, such as the ADHD Rating Scale, are commonly used to assess the severity and frequency of ADHD symptoms. These scales provide additional information to aid in diagnosis and treatment planning.

IJIRMPS1730 Website: www.ijirmps.org Email: editor@ijirmps.org 1

#### **Medications:**

- a. Stimulant Medications: Stimulant medications, such as methylphenidate (e.g., Ritalin) and amphetamines (e.g., Adderall), are commonly prescribed for ADHD. These medications help regulate neurotransmitters in the brain, improving attention, reducing hyperactivity, and enhancing impulse control.
- b. Non-Stimulant Medications: In cases where stimulants are not suitable or well-tolerated, non-stimulant medications like atomoxetine (Strattera) or certain antidepressants may be considered. These medications also target neurotransmitter imbalances associated with ADHD.
- c. Medication Monitoring: Regular follow-up visits with the psychiatrist are essential to monitor the response to medication, adjust dosages as needed, and manage any potential side effects. Close collaboration between the psychiatrist, patient, and caregivers is crucial for optimal medication management.

## Psychological Interventions:

- a. Behavioral Therapy: Behavioral therapy, such as cognitive-behavioral therapy (CBT) or behavioral parent training, can be beneficial for individuals with hyperactivity. These interventions focus on improving time management, organizational skills, problem-solving abilities, and behavior management strategies.
- b. Psychoeducation and Support: Providing psychoeducation to patients, families, and teachers helps them understand ADHD and develop appropriate strategies for managing symptoms. Support groups or therapy can also provide emotional support and guidance for individuals and their families.

#### Tests:

- a. Neuropsychological Testing: Neuropsychological testing may be recommended to assess cognitive functioning, identify strengths and weaknesses, and rule out other underlying conditions that may contribute to hyperactivity.
- b. Continuous Performance Tests: Continuous performance tests, such as the Conners' Continuous Performance Test (CPT), assess sustained attention, impulse control, and vigilance. These tests can provide additional objective data to aid in diagnosis and treatment monitoring.
- c. Monitoring Side Effects: Regular monitoring of potential side effects of medication is essential. This may involve physical examinations, blood pressure checks, and laboratory tests to ensure the medication is well-tolerated and safe for the patient.

Psychiatry, in collaboration with other healthcare professionals, plays a vital role in the comprehensive management of hyperactivity, particularly in the context of ADHD. Through a combination of psychiatric assessment, appropriate medications, psychological interventions, and relevant tests, individuals with hyperactivity can receive tailored treatment to mitigate the impact of symptoms and improve their overall functioning and quality of life.

#### Methods

A review of relevant literature was conducted to examine the efficacy and safety of psychiatric medications and tests in patients with hyperactivity. Studies focusing on the use of medications, such as stimulants, non-stimulants, and other psychiatric drugs, were included in the review. Additionally, research on diagnostic tests, such as neuropsychological assessments and brain imaging studies, was considered to evaluate their utility in the management of hyperactivity.

### **Results**

Psychiatric medications, particularly stimulants like methylphenidate and amphetamines, have shown significant benefits in reducing hyperactivity and improving attention in patients with ADHD. Non-stimulant medications, such as atomoxetine and guanfacine, are also effective alternatives for individuals who may not tolerate stimulants. In addition to medications, diagnostic tests like neuropsychological assessments can provide valuable insights into patients' cognitive functioning and help tailor treatment plans accordingly.

## Discussion

While psychiatric medications and tests play a crucial role in the management of hyperactivity, it is essential to consider the individualized nature of treatment. Each patient may respond differently to medications, requiring careful monitoring and adjustment of dosage to achieve optimal outcomes. Likewise, diagnostic tests should be used in conjunction with clinical evaluations to offer a comprehensive understanding of

IJIRMPS1730 Website: www.ijirmps.org Email: editor@ijirmps.org 2

patients' needs. Collaborative efforts between psychiatrists, psychologists, and other healthcare professionals are essential in developing holistic treatment plans for patients with hyperactivity.

#### Conclusion

Psychiatry offers a wide range of interventions for patients with hyperactivity, including medications and tests that can effectively manage symptoms and improve overall functioning. While medications like stimulants and non-stimulants have demonstrated efficacy in reducing hyperactivity, diagnostic tests can provide valuable information to guide treatment decisions. Individualized care that considers patients' unique needs and preferences is essential in the successful management of hyperactivity. Further research is needed to explore novel treatment options and enhance the quality of care provided to patients with hyperactivity.

### **REFERENCES:**

- 1. Faraone, S. V., & Buitelaar, J. (2010). Comparing the efficacy of stimulant medications for ADHD using meta-analysis. European Child & Adolescent Psychiatry, 19(4), 353-364.
- 2. Swanson, J. M., & Volkow, N. D. (2009). Psychopharmacology for the clinician. Journal of Child Psychology and Psychiatry, 50(1-2), 75-81.
- 3. Cortese, S., & Coghill, D (2018). Twenty years of research on attention-deficit/hyperactivity disorder (HD): looking back, looking forward. Evidence-Based Mental Health, 21(4), 173-176.
- 4. Froehlich, T. E., Lanphear, B. P., & Epstein, J. N. (2007). Barriers to action in attention-deficit/hyperactivity disorder. Pediatrics, 120(4), e857-e864.
- 5. Volkow, N. D., & Swanson, J. M. (2013). Clinical practice: Adult attention deficit-hyperactivity disorder. New England Journal of Medicine, 369(20), 1935-1944.
- 6. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders5th ed.). American Psychiatric Publishing.
- 7. Banaschewski, T., Coghill, D., Santosh, P., & Zuddas, A. (2011). The pharmacology of attention-deficit/hyperactivity disorder. In: Coghill D, Banaschewski T, Zuddas A (eds). Oxford Textbook of Attention Deficit Hyperactivity Disorder. Oxford University Press.
- 8. Brown, A. S., & Schubert, D. S. (2017). Diagnosis and management of attention deficit hyper disorder in primary care for school-age children and adolescents. Pediatrics in Review, 38(2), 51-61.
- 9. Stahl, S. M. (2014). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press.
- 10. Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., ... & Gluud, C. (2015). Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses. BMJ, 351, h5203.

IJIRMPS1730 Website: www.ijirmps.org Email: editor@ijirmps.org 3